FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2026/01/101034 [Registered on: 14/01/2026] Trial Registered Prospectively
Last Modified On: 22/12/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Other 
Public Title of Study   To Study The Effect Of Eranda Beeja Payasa And Rasanadi Guggul In The Management Of Gridhrasi (Sciatica) 
Scientific Title of Study   A Comparative Clinical Study Of Eranda Beeja Payasa And Rasanadi Guggul In The Management Of Gridhrasi With Special Reference To Sciatica 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Beenish Rafiq 
Designation  M.D. Scholar 
Affiliation  Jammu Institute Of Ayurveda And Research 
Address  P.G. Department Of Kayachikitsa Jammu Institute Of Ayurveda And Research, Nardani Bajwan, Bantalab Jammu Jammu And Kashmir 181123

Jammu
JAMMU & KASHMIR
181123
India 
Phone  6005584366  
Fax    
Email  beenishrafiq8@gmail.com  
 
Details of Contact Person
Scientific Query  
Name  Dr Sourabh Gupta 
Designation  Associate Professor 
Affiliation  Jammu Institute Of Ayurveda And Research 
Address  P.G. Department Of Kayachikitsa Jammu Institute Of Ayurveda And Research, Nardani Bajwan, Bantalab Jammu Jammu And Kashmir 181123

Jammu
JAMMU & KASHMIR
181123
India 
Phone  9419312498  
Fax    
Email  sourabh.gupta32@gmail.com  
 
Details of Contact Person
Public Query  
Name  Dr Beenish Rafiq 
Designation  M.D Scholar 
Affiliation  Jammu Institute Of Ayurveda And Research 
Address  P.G. Department Of Kayachikitsa Jammu Institute Of Ayurveda And Research, Nardani Bajwan, Bantalab Jammu Jammu And Kashmir 181123

Jammu
JAMMU & KASHMIR
181123
India 
Phone  6005584366  
Fax    
Email  beenishrafiq8@gmail.com  
 
Source of Monetary or Material Support  
Jammu Institute Of Ayurveda And Research , Nardni, Jammu, Jammu And Kashmir, 181123, INDIA 
 
Primary Sponsor  
Name  Jammu Institute Of Ayurveda And Research 
Address  Jammu Institute Of Ayurveda And Research,Nardani Bajwan,Bantalab Jammu Jammu And Kashmir, 181123 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Beenish Rafiq  Jammu Institute Of Ayurveda And Research  P.G. Department Of Kayachikitsa, OPD and IPD of hospital Jammu Institute Of Ayurveda And Research, Nardani Bajwan, Bantalab Jammu, Jammu And Kashmir 181123
Jammu
JAMMU & KASHMIR 		 6005584366

beenishrafiq8@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Jammu Institute of Ayurveda & Research  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:M543||Sciatica. Ayurveda Condition: GRUDHRASI,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmDrugClassical(1) Medicine Name: Eranda Beeja Payas, Reference: Bhaishajya Ratnavali By chaukambha sanskrit sansthan vidhyotini tikska vata vyadhi Gridhrasi chikitsa shlok no 42, Route: Oral, Dosage Form: Ksheerpaka, Dose: 40(ml), Frequency: bd, Bhaishajya Kal: Pragbhakta, Duration: 30 Days, anupAna/sahapAna: No, Additional Information: -Follow up :- on 15th day, 30th day and 45th day -Drug free Follow up :- on 45th day
2Comparator ArmDrugClassical(1) Medicine Name: Rasana Guggul vati, Reference: Yogaratnakara with Vidyotini hindi commentary by Vd. Laksmipati Shastri edited by Brahmasankar www.wjpls.org│Vol 9, Issue 4, 2023.│World Journal of Pharmaceutical and Life Science Shastri; pub. by Chaukhambha Sanskrit Sansthan, Varanasi; Uttarardh, chapter Vata Vyadhi chikitsa page no 523 shloka no 1, Route: Oral, Dosage Form: Gutika/Vati/Ghana Vati/ Tablets, Dose: 500(mg), Frequency: bd, Bhaishajya Kal: Pragbhakta, Duration: 30 Days, anupAna/sahapAna: No, Additional Information: -Follow up :- on 15th day, 30th day and 45th day -Drug free Follow up :- on 45th day
 
Inclusion Criteria  
Age From  25.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  1.Patients between the age group of 25 – 60 years.
2.Patient representing signs and symptoms of Gridhrasi who are willing to participate in study.
3.Subjects willing to participate with written informed consent, which is conveyed in the language which the subject can understand.
4.Both males and female will be selected.
 
 
ExclusionCriteria 
Details  1.Age below 25 years and above 60 years.
2.Patients suffering from Cardiac Diseases.
3.Uncontrolled Diabetes Mellitus, Hypertension.
4.Cancer of Lumbo-Sacral spine.
5.Tuberculosis of vertebral column.
6.Pregnant and lactating women.
7. Patient suffering from Ankylosing spondylitis, sacroiliac arthritis, herpes simplex infection causing radiating pain, disc prolapse, degenerative changes, bony osteophytic growth.
8.Any trauma related to Lumbo-sacral spine.
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   On-site computer system 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Improvement in subjective and objective parameters of Gridhrasi (Sciatica) :
SUBJECTIVE CRITERIA -
TODA,RUK, STAMBHA, SPANDANA, GAURAVA, ARUCHI, TANDRA
OBJECTIVE CRITERIA -
VAS SCORE, SLR TEST, BRAGARD’S TEST
 		 Assessment : Percentage relief in symptoms and signs after 30 days of treatment. 
 
Secondary Outcome  
Outcome  TimePoints 
1.Improvement in Functional Mobility
2.Reduction in Associated Symptoms
3.Enhancement in Quality of Daily Activities
 		 After successful completion of treatment on 45th day. 
 
Target Sample Size   Total Sample Size="30"
Sample Size from India="30" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2 
Date of First Enrollment (India)   01/05/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
This randomized, open-label, comparative clinical study evaluates the efficacy of Eranda Beeja Payas in the management of Gridhrasi (sciatica) in comparison with Rasanadi Guggul, based on Ayurvedic principles. Gridhrasi, described in classical texts as a Vata Vyadhi presenting with Stambha, Ruk, Toda, and Spandana, closely parallels modern sciatica caused by compression or irritation of the sciatic nerve. Considering the limitations of contemporary treatments and the high prevalence of low back pain and sciatica, this study aims to explore an effective, non-invasive Ayurvedic intervention.

A total of 30 patients (aged 25–60 years) meeting diagnostic criteria of Gridhrasi will be randomly allocated into two groups of 15 each. Group A will receive Eranda Beeja Payas prepared as per classical guidelines, with dosage tailored to the patient’s Agni for 30 days. Group B will receive Rasanadi Guggul (500 mg BD). Follow-ups will occur on Day 15, 30, and 45, including drug-free follow-up on Day 45. Assessment will be based on both subjective parameters (Toda, Ruk, Stambha, Spandana, Gaurava, Aruchi, Tandra) and objective parameters (VAS score, SLR test, Bragard’s test). Data will be statistically analyzed to determine comparative therapeutic efficacy.

The primary objective is to assess whether Eranda Beeja Payas offers significant improvement in symptoms of Gridhrasi relative to Rasanadi Guggul. Results will contribute to evidence-based validation of classical Ayurvedic formulations used in Vata-Vyadhi management.
 
Close